Combinatorial Targeting of Leukemia and Stromal Cells Overcomes Fms-like Tyrosine Kinase 3 (FLT3) Inhibitor Resistance in Acute Myeloid Leukemia (AML)

被引：0
|
作者：
Bhattacharya, Seemana [1 ,2 ]
Mu, Hong [1 ,2 ]
Piya, Sujan [1 ,2 ]
Zhang, Weiguo [1 ,2 ]
McQueen, Teresa [1 ,2 ]
Paradiso, Linda [3 ]
Oberkovitz, Galia [4 ]
Benami, Eyal [4 ]
Andreeff, Michael [1 ,2 ]
Borthakur, Gautam [1 ,2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Houston, TX 77030 USA
[3] Strategia Therapeut Inc, 28420 Hardy Toll Rd,Suite 110, Spring, TX USA
[4] BioLineRx Ltd, Modiin Technol Pk 2,HaMaayan St, Modiin, Israel
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷
关键词：
AML; FLT3-ITD; dual MEK1-FLT3 inhibitor; peptidic CXCR4-antagonist; leukemia-stroma interactions;
D O I：
10.1016/j.clml.2017.07.049
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-033
引用
收藏
页码：S273 / S273
页数：1
相关论文
共 50 条
  • [1] Efficacy of FMS-like Tyrosine Kinase 3 (FLT3) inhibitors in patients with acute myeloid leukemia
    Htut, T. W.
    Ball, S.
    Khandelwal, N.
    Wongsaengsak, S.
    Mogollon-Duffo, F.
    Jahan, N.
    Quirch, M.
    D'cunha, N.
    Thein, K. Z.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 52 - 53
  • [2] Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia
    Swords, R.
    Freeman, C.
    Giles, F.
    LEUKEMIA, 2012, 26 (10) : 2176 - 2185
  • [3] FMS-like Tyrosine Kinase 3 (FLT3) Gene as a Significant Biomarker for Acute Myeloid Leukemia
    Fotra, Roopali
    Kour, Jyotdeep
    Mahajan, Deepti
    Kumar, Parvinder
    Dhar, Manoj K.
    BIOSCIENCE BIOTECHNOLOGY RESEARCH COMMUNICATIONS, 2020, 13 (01): : 280 - 283
  • [4] Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia
    R Swords
    C Freeman
    F Giles
    Leukemia, 2012, 26 : 2176 - 2185
  • [5] Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML)
    Ravandi, F.
    Jilani, I.
    Estey, E.
    Kantarjian, H.
    Dey, A.
    Aguilar, C.
    Jitkaroon, C.
    Giles, F.
    O'Brien, S.
    Keating, M.
    Albitar, M.
    LEUKEMIA RESEARCH, 2007, 31 (06) : 791 - 797
  • [6] A ZEBRAFISH MODEL OF FMS-LIKE TYROSINE KINASE 3 (FLT3) IN DEFINITIVE HEMATOPOIESIS AND HUMAN ACUTE MYELOID LEUKEMIA
    He, Bailiang
    Man, Cheuk Him
    Shi, Xiangguo
    Ma, Alvin C. H.
    Leung, Anskar Y. H.
    EXPERIMENTAL HEMATOLOGY, 2013, 41 (08) : S48 - S48
  • [7] Combined effect of midostaurin and sphingosine kinase-1 inhibitor on FMS-like tyrosine kinase 3 (FLT3) wild type acute myeloid leukemia cells
    Sahin, Hande Nur
    Adan, Aysun
    TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2022, 47 (01): : 49 - 58
  • [8] Fms-like tyrosine kinase 3 positive acute myeloid leukemia
    Isidori, Alessandro
    Visani, Giuseppe
    Ferrara, Felicetto
    CURRENT OPINION IN ONCOLOGY, 2023, 35 (06) : 589 - 593
  • [9] HM43239, a Novel Potent Small Molecule FLT3 Inhibitor, in Acute Myeloid Leukemia (AML) with FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1 /2 Study
    Daver, Naval G.
    Lee, Kyoo Hyung
    Yoon, Sung-Soo
    Jung, Chul Won
    Kang, Hyun Jeong
    Jung, Sooa
    Seo, Sujin
    Yoon, Jiyeon
    Kim, Hyunjin
    Noh, Young Su
    Seo, Yoonha
    Kwon, Hyeyoung
    Han, Oakpil
    Baek, Seungjae
    Seo, Kyounghee
    Suh, Kwee Hyun
    BLOOD, 2019, 134
  • [10] HM43239, a Novel Small Molecule Inhibitor of FLT3, in Acute Myeloid Leukemia (AML) with and without FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1/2 Study
    Daver, Naval
    Lee, Kyoo Hyung
    Jung, Chul Won
    Soo, Yoon Sung
    Arellano, Martha L.
    Jonas, Brian A.
    Yoon, Jiyeon
    Jung, Sooa
    Noh, Young Su
    Bae, Inhwan
    Kim, Song
    BLOOD, 2020, 136
12345